Hyaluronic acid (HA) has been shown to affect angiogenesis and the function of the blood-brain barrier (BBB) and a crucial role for HA in atherosclerosis has been described. We have recently demonstrated changes in the levels of HA in cerebrospinal fluid (CSF) in patients with Alzheimer's disease (AD) with documented vascular alterations. To further investigate if the level of HA in CSF can be used as a clinical diagnostic biomarker to identify vascular pathology in dementia, we analyzed the levels of HA in the CSF of patients with vascular dementia (VaD) (n=46), AD (n=45), and controls without dementia (n=26). In line with our previous data, we found significantly increased levels of HA in CSF from patients with VaD compared with controls, whereas the levels of HA in patients with AD were found to be unaltered compared with controls and patients with VaD. We also detected increased levels of HA in individuals with vascular changes determined as significant white matter changes or previous infarction on cranial computed tomography or magnetic resonance imaging, compared with individuals without these findings. Furthermore, we found a significant positive correlation between the levels of HA and the CSF/serum albumin ratio, an indicator of BBB integrity, in patients with VaD and AD, supporting the role of HA in vascular changes in the brain. Our results indicate a potential diagnostic value for the detection of vascular brain changes in dementia using CSF levels of HA, but emphasize the importance of further development of more sensitive HA assays.
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INTRODUCTION
Hyaluronic acid (HA), chains of nonsulfated glycosaminoglycan, is often referred to as the backbone of the extracellular matrix (ECM), which provides biochemical and physical support to multicellular structures [1] . In vessels, HA together with other ECM molecules form a luminal mesh called glycocalyx [1] . The function of glycocalyx is to modulate vascular integrity, for example, by sieving molecules along the capillary wall [2, 3] and regulating adherence and migration of blood-derived immune cells [4] . The role of HA and glycocalyx in vascular integrity became apparent when pathologic changes in vessel function were investigated.
Neointimal formation is markedly enhanced when HA is overexpressed [5] and degradation/shedding of HA increases glycocalyx permeability [6] . Moreover, inhibition of HA production reduces the thickness of glycocalyx, increases leukocyte rolling, and accelerates the burden of aortic plaque [7] . A crucial role for HA in atherosclerosis has been demonstrated in a number of studies [8] .
Levels of shedded soluble HA can be measured in blood and cerebrospinal fluid (CSF) [9] [10] [11] and could thus theoretically function as a diagnostic marker reflecting glycocalyx degradation and vascular dysfunction. Increased levels of HA in CSF from stroke patients have been reported [9] . In addition, we have recently demonstrated increased levels of HA in CSF from patients with Alzheimer's disease (AD) with vascular changes and a strong correlation between the levels of HA in CSF and Q-albumin (CSF/serum albumin ratio), an indicator of the function of the bloodbrain barrier (BBB) [10] . To further investigate the potential diagnostic value of HA for vascular dementia (VaD) , in this study we analyze HA in a new patient cohort consisting of controls without dementia and patients with AD and VaD.
MATERIALS And METHODS

Patients
Samples of CSF from patients diagnosed with AD (n=45) or VaD (n=46), and controls without dementia (n=27) were obtained at the Memory Clinic at Skåne University Hospital (Sweden). The controls were individuals referred for evaluation of subtle cognitive symptoms. After the diagnostic dementia work-up, they were judged to be cognitively healthy. The dementia diagnoses were made according to the DSM-IIIR criteria of dementia [12] combined with the NINCDS-ADRDA criteria [13] for AD and NINDS-AIREN criteria for VaD [14] . All individuals underwent computed tomography (CT) or magnetic resonance imaging (MRI) of the brain before lumbar puncture. CT (n=91) or MRI scans (n=15) were retrieved for the controls (n=26), patients with AD (n=35) and patients with VaD (n=45), and rated for signs of vascular changes defined as the presence of (1) white matter changes (WMC) grade 2 according to Wahlund (beginning confluence of lesions) in any region, left and right frontal and parietal lobes as well as the basal ganglia and insula [15] , or (2) tissue defects with a characteristic appearance of previous infarction or hemorrhage.
Individuals were classified as having cerebrovascular changes or not ( Table 1 ). The number of individuals exposed to head trauma, inflammatory diseases, increased levels of C-reactive protein (CRP) or peripheral tumors earlier in life was identified through review of the medical records ( Table 1 ). The Mini Mental State Examination (MMSE) [16] was used to evaluate the cognitive status of the patients and controls.
The ethics committee of Lund University approved the study and the study procedures were conducted in accordance with the Helsinki declaration of 1975 (revised in 2000). All participants gave informed consent to the research.
Analysis of HA, Q-albumin and AD markers
Levels of HA in CSF were determined using a commercially available enzyme-linked immunosorbent assay (ELISA) kit (R&D Systems, Minneapolis, MN)
according to the manufacturer's instructions. Levels of albumin in serum and CSF were determined by nephelometry using the Behring nephelometer analyzer (Behringwerke AG, Marburg, Germany). The basic CSF AD biomarker (Aβ1-42, Ttau, P-tau181) profile of the patients included in the study was analyzed routinely by commercial ELISA (Innogenetics, Ghent, Belgium) as previously described [17] .
Statistical analysis
Statistical analysis was performed using SPSS software (version 20.0 for Windows, SPSS Inc., Chicago, IL). The Kolmogorov-Smirnov test was used to test for normal distribution of the variables. The independent sample t test was used for comparisons between two groups. For comparisons between more than two groups, one-way analysis of variance (ANOVA), followed by Bonferroni post hoc correction, was used (comparisons, n=3). Correlations were investigated using the Spearman correlation test. The results are presented as medians or means±standard deviation or range. A P value <0.05 was considered significant.
RESULTS
Demographic data
The demographic data for the individuals included in the study are presented in Table 1 
Levels of HA in CSF
The controls were younger than the patients with AD and VaD, therefore we analyzed the association between age and levels of HA in CSF before further statistical analysis. No significant correlation between the two variables was found in any of the groups (data not shown) and hence HA levels were not adjusted for age before comparison analysis. Furthermore, the levels of HA in CSF from individuals with previous head trauma, inflammatory disease, and peripheral tumors did not significantly differ compared with individuals not exposed to similar conditions (data not shown). Similarly, individuals with abnormally high levels of CRP did not show altered levels of HA compared with individuals with normal CRP levels (data not shown).
Multicomparison analysis showed a significant difference in levels of HA in CSF between the groups analyzed (ANOVA, P=0.041); patients with VaD had significantly higher levels of HA compared with controls (P=0.035), but not compared with patients with AD (P=0.948) (Fig. 1A) . Levels of HA in patients with AD did not differ significantly compared with controls (P=0.285) (Fig. 1A) . We also (Fig. 1B) .
Correlation analysis
In line with our previous study, we found a significant correlation between HA and Q-albumin in patients with both AD and VaD (r=0.535, P<0.001 and r=0.445, P=0.002, respectively) ( Fig. 2A and B Neither P-tau nor T-tau were associated with HA levels in any of the groups investigated (data not shown). were compared within each dementia group. However, this increase was not statistically significant, which may be due to lack of statistical power.
DISCUSSION
HA varies greatly in length and the properties of the molecule are determined by its size. The major form of HA in vivo has a molecular weight of about 1 million kDa and it is incorporated into the stabilizing glycocalyx [3] . In addition, soluble forms of high molecular weight (HMW) HA exist and experimental studies demonstrate that this form has protective, antiinflammatory and antiangiogenic properties [19, 20] . However, in response to pathologic events such as inflammation or damage, HA is degraded into low molecular weight (LWM) chains (<500 kDa) [21] . LMW HA has proinflammatory and proangiogenic properties [19, 20, 22] . Our HA assay, like all the available immunoassays for determining HA, does not distinguish between LMW and HMW. This is undoubtedly a limitation of the present study, since we consequently can not specify whether the increased amount of HA is due to a higher amount of LMW or HMW or both. Moreover, a recent methodological study has shown that HMW HA tends to yield a higher signal in HA immunoassays compared with LMW HA, although the concentration of the two HA samples is the same [23] . It may thus be that the differences in the CSF HA concentration found in our current study is in reality even higher given the possibility that most HA in patients with VaD and AD is the degraded LMW version.
The role of HA in vascular changes is further supported by the correlation between HA levels and Q-albumin in patients with AD and VaD. Q-albumin (i.e., the CSF/serum albumin ratio) is commonly used as a crude indicator of BBB function, because increased influx of albumin from blood to the CSF indicates enhanced BBB permeability. Intactness of the BBB depends on a well-functioning neurovascular unit, where the endothelial wall, tight junctions, and transporters are considered to be the key components [24] . Under pathologic conditions (such as hypoxia/ischemia), inflammatory processes disturb the microvascular integrity by disrupting endothelial tight junctions and transporters, and thereby increase the permeability of the BBB [24] . As mentioned in the introduction, glycocalyx also plays a specific role in microvascular integrity and BBB intactness because it sieve larger proteins, including albumin, leaving mainly water and smaller molecules to pass through the BBB [3] .
Experimental studies have shown that HA binds albumin and removal of HA reduces glycocalyx albumin absorption [25] . The positive association between HA and Qalbumin in patients with dementia may thus reflect a pathology-provoked increase in degradation and shedding of HA, causing a thinner glycocalyx mesh with less albumin bindings sites, which in turn increases the amount of albumin passing through the BBB.
We also found a significant negative correlation between MMSE and HA in patients with AD. However, this correlation was not found in the controls only; a tendency to correlation was noted in the patients with VaD. This finding was not reproduced in our previous study in either of the diagnostic groups investigated [10] , which highlights the importance of further investigation of the link between HA, in particular LMW HA, and cognition in larger patients cohorts.
Further, we found a weak tendency to a negative association between HA and the AD biomarker A1-42 in the AD group. Although this correlation was not significant it may support previous studies describing A1-42 as one of the culprits underlying vascular changes found in AD patients. Lowered levels of A1-42 in CSF correlates with increased load of A1-42 plaques in the brain [26] , the hallmark of AD pathology. Hence the negative trend indicates increased HA shedding along with increased A1-42 plaque load. Interestingly, preclinical in vitro studies, using the Tg2576 AD mouse model, have shown that accumulation of toxic A1-42 is preceding hypervascularization, tight junction disruption and BBB dysfunction [27, 28] and that active Aβ immunization reverse these pathological events [29, 30] . The link between HA and atherosclerosis mentioned previously [35] is interesting given that atherosclerosis is regarded as one of the major risk factors for dementia [36] . In addition, neuropathologic examinations have revealed atherosclerosis in patients with AD and VaD [37, 38] . From this perspective, it may be hypothesized that an alteration in HA production or degradation of glycocalyx, is an early event leading toward progression of dementia. In support, an interesting experimental in vivo study recently demonstrated accelerated atherosclerosis and severe damage in glycocalyx in rodents chronically treated with the HA synthesis inhibitor, 4-methylumbelliferone [7] . However, although this study suggests failure of glycocalyx function as a key event in the early stages of atherosclerosis, there is no direct evidence demonstrating increased HA degradation as the primary underlying cause of atherosclerosis. Our study demonstrates a link between increased HA degradation and vascular changes in the brain. We were unable to retrieve information on atherosclerosis in the individuals investigated in this study. Therefore we lack evidence of a direct link between this degradation and atherosclerosis. Further studies investigating the role of HA in the atherosclerotic process and VaD in the long term are therefore highly warranted.
We conclude that HA, as measured with the currently available HA immunoassays, does not fulfill the criteria of a valuable diagnostic biomarker for Tumors, n (%) 1 (4) 2 (4) 8 (17) Data are presented as means±SD. ***Indicates a significant difference at the p<0.001 level compared with controls using ANOVA.
a Data missing (n=4).
b Data missing (n=10).
c Data missing (n=1). 
